secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-152050
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology appoints Jeff Knight as Chief Development and Operating Officer
----------------------------------------------------------------------------

- Jeff Knight, former CDOO at Crinetics, appointed effective April 13, 2026; role includes clinical development and operations.
- Compensation: $565k base salary, 40% annual target bonus, and stock option for 800k shares under 2025 Inducement Plan.
- Knight brings 30+ years experience; previously at Poseida, Halozyme, Amgen, and Genentech.
- Company highlights upcoming catalysts for evorpacept and ALX2004 programs in next 12-18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526152050/0001193125-26-152050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526152050/alxo-20260413.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-152050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer